



Contents lists available at ScienceDirect

European Journal of Medicinal Chemistry

journal homepage: <http://www.elsevier.com/locate/ejmech>

Research paper

Structural modifications in the distal, regulatory region of histamine H₃ receptor antagonists leading to the identification of a potent anti-obesity agent

Katarzyna Szczepańska^a, Steffen Pockes^{b,*}, Sabina Podlewska^{a,c}, Carina Höring^b, Kamil Mika^d, Gniewomir Latacz^a, Marek Bednarski^d, Agata Siwek^e, Tadeusz Karcz^a, Martin Nagl^b, Merlin Bresinsky^b, Denise Mönnich^b, Ulla Seibel^b, Kamil J. Kuder^a, Magdalena Kotańska^d, Holger Stark^f, Sigurd Elz^b, Katarzyna Kieć-Kononowicz^{a,**}

^a Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków, 30-688, Poland

^b Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstraße 31, D-93053, Regensburg, Germany

^c Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, Kraków, 31-343, Poland

^d Department of Department of Pharmacological Screening, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków, 30-688, Poland

^e Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków, 30-688, Poland

^f Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225, Duesseldorf, Germany

ARTICLE INFO

Article history:

Received 28 August 2020

Received in revised form

7 November 2020

Accepted 16 November 2020

Available online xxx

Keywords:

Histamine H₃ receptor

Non-imidazole histamine H₃R ligands

Piperazine derivatives, Selective ligands

Molecular docking

Anti-obesity agents

ABSTRACT

A series of 4-pyridylpiperazine derivatives with varying regulatory region substituents proved to be potent histamine H₃ receptor (H₃R) ligands in the nanomolar concentration range. The most influential modification that affected the affinity toward the H₃R appeared by introducing electron-withdrawing moieties into the distal aromatic ring. In order to finally discuss the influence of the characteristic 4-pyridylpiperazine moiety on H₃R affinity, two Ciproxifan analogues **2** and **3** with a slight modification in their basic part were obtained. The replacement of piperazine in **3** with piperidine in compound **2**, led to slightly reduced affinity towards the H₃R ($K_i = 3.17$ and 7.70 nM, respectively). In fact, **3** showed the highest antagonistic properties among all compounds in this series, hence affirming our previous assumptions, that the 4-pyridylpiperazine moiety is the key element for suitable interaction with the human histamine H₃ receptor. While its structural replacement to piperidine is also tolerated for H₃R binding, the heteroaromatic 4-pyridyl moiety seems to be essential for proper ligand-receptor interaction. The putative protein-ligand interactions responsible for their high affinity were demonstrated using molecular modeling techniques. Furthermore, selectivity, intrinsic activity at the H₃R, as well as drug-like properties of ligands were evaluated using *in vitro* methods. Moreover, pharmacological *in vivo* test results of compound **9** (structural analogue of Abbott's A-331440) clearly indicate that it may affect the amount of calories consumed, thus act as an anorectic compound.

© 2020 Elsevier Masson SAS. All rights reserved.

1. Introduction

The histamine H₃ receptor (H₃R) has been pharmacologically discovered in 1983 as presynaptic autoreceptor [1] involved in a negative feedback modulation of histamine synthesis and inhibition of its release from histaminergic neurons [1]. On the other

hand, as postsynaptic H₃ heteroreceptors they also modulate the release of other neurotransmitters such as dopamine, acetylcholine, serotonin, norepinephrine, γ -aminobutyric acid, glutamate, substance P [2–4]. The H₃R is expressed predominantly in the central nervous system (CNS), especially in the regions associated with cognition, sleep, wakefulness and homeostatic regulation [5]. Regarding the distribution of the H₃R in the body combined with its regulatory impact on essential neurotransmitters, H₃R-inhibiting compounds (antagonists/inverse agonists) represent a highly attractive class of ligands in the search for new drugs.

* Corresponding author.

** Corresponding author.

E-mail addresses: steffen.pockes@ur.de (S. Pockes), mfkonono@cyf-kr.edu.pl (K. Kieć-Kononowicz).

